<DOC>
	<DOCNO>NCT02470208</DOCNO>
	<brief_summary>The purpose study evaluate ability T-SPOT.CMV assay determine immune competence CMV infection stem cell transplantation . To determine utility T-SPOT.CMV assay use transplantation determine immune competence subsequent CMV reactivation determine utility T-SPOT.CMV assay use transplantation determine immune competence subsequent CMV reactivation .</brief_summary>
	<brief_title>Observational Trial Evaluate Hematopoietic Stem Cell Transplantation CMV Reactivation</brief_title>
	<detailed_description>In prospective , non-randomized , observer-blind observational study , 200 patient meet study 's eligibility criterion enrol 20 study center . Enrollment actively manage sponsor . Blood sample collect 14 day transplantation , 2-week interval 6 month transplant procedure . Study duration : 15 month : 9 month enroll patient , 6 month ( 182 day ) participation patient .</detailed_description>
	<criteria>1 . Age â‰¥18 year . 2 . Patients undergo one follow type allogeneic transplantation : match related donor , match mismatch unrelated donor , haploidentical , cord blood . 3 . Patients must seropositive CMV prior transplantation , regardless donor seropositivity . 4 . Institutional Review Board ( IRB ) approve write Informed Consent privacy agreement per national regulation ( e.g. , Health Insurance Portability Accountability Act [ HIPAA ] sit USA ) must obtain patient patient 's legally authorize representative prior studyspecific procedure . 5 . Patients must consider suitable study Investigator . 1 . Patients know active CMV reactivation within 1 month prior enrollment study 's pretransplant screening period . 2 . Patients receive antiviral therapy active CMV acyclovir valacyclovir ( i.e. , foscarnet , ganciclovir , valganciclovir , cidofovir ) month prior enrollment . 3 . Patients previously receive plan receive CMV vaccine . 4 . Patients know hepatitis B , hepatitis C , human immunodeficiency virus ( HIV ) positive . 5 . Patients know clinically significant medical psychiatric condition consider high risk participation investigational study . 6 . Patients participate plan participate CMVrelated drug vaccine study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Cytomegalovirus reactivation stem cell transplant</keyword>
</DOC>